Better Health for All

BridgeBio Pharma's core business is entirely focused on developing transformative medicines for genetic diseases and cancers, with 3 FDA-approved therapies

and a pipeline of over 30 development programs. Its product Attruby (acoramidis) reduces cardiovascular death and hospitalization with an 81% absolute survival rate and was well-tolerated with no safety signals. The company has no revenue from products with significant negative health impacts. BridgeBio offers comprehensive patient assistance programs for Attruby, including a copay assistance program reducing costs to as little as $0 per month for eligible commercially insured patients, a 1-month free trial, and a patient assistance program providing the drug at no cost for eligible uninsured or limited coverage patients. A QuickStart program is also available for coverage decision delays. The company invested $300 million in GondolaBio, a spinout focused on rare diseases, and has $406 million in cash, with an anticipated $500 million from acoramidis FDA approval and $105 million in regulatory milestones in 1H 2025. BridgeBio provides clear disclosures of adverse reactions for Attruby, including diarrhea (11.6% vs 7.6% placebo) and upper abdominal pain (5.5% vs 1.4% placebo), with similar discontinuation rates (9.3% vs 8.5% placebo). Patient consent is required for enrollment in its ForgingBridges support program.

Fair Pay & Worker Respect

BridgeBio Pharma, Inc. reported a CEO-to-median employee pay ratio of 45:1 in 2024, with the CEO's total compensation at $15,581,923 and median employee pay at $348,914.

The company states that none of its employees are represented by a labor organization or covered by collective bargaining agreements. BridgeBio offers physical and mental health benefits to all employees who work at least 30 hours per week, on average. Employee engagement, based on Glassdoor reviews, shows an overall rating of 4.1 out of 5 stars and a 74% recommendation rate.

Fair Trade & Ethical Sourcing

No specific, quantitative evidence regarding BridgeBio Pharma, Inc.'s fair trade and ethical sourcing practices was found in the provided articles. The documents include a Code of Business Conduct and Ethics

, corporate presentation archives , and general ESG risk ratings , none of which contain the necessary data points to score the company against the defined KPIs such as fair-trade certification share, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.

Honest & Fair Business

BridgeBio Pharma has a formal Whistleblower Policy that allows confidential and anonymous reporting, including through EthicsPoint, and explicitly prohibits retaliation against those who report in good faith.

The company's Code of Business Conduct and Ethics establishes policies to promote ethical practices and conduct, committing to comply with the FCPA and other anti-corruption laws and regulations. It explicitly states that the company does not permit or condone bribes, kickbacks, or other improper payments. The 1940 Act requires that a majority of the company's directors be persons other than 'interested persons.' The company engages independent valuation firms to assist in determining the fair value of selected portfolio investments each quarter, but the scope of these services is at the Board's discretion, and the Board remains solely responsible for the final determination of fair value.

Kind to Animals

BridgeBio Pharma conducts extensive animal testing, including repeat-dose toxicity studies in rats (up to 26 weeks) and dogs (up to 39 weeks), genetic toxicology, carcinogenicity studies (two-year in rats, 26-week in mice), and reproductive toxicology studies in rats and rabbits.

Early proof-of-concept animal studies are also underway for programs like BBP-815. While in vitro and ex vivo pharmacology studies are conducted, and animal models for certain conditions like ATTR amyloidosis are unavailable, the company's preclinical studies consistently involve animal models for safety and efficacy rationale. Sustainalytics reports the company has 'Significant Involvement' in animal testing. The company's policy is vague, with routine non-essential testing continuing unabated, as evidenced by the variety and duration of animal tests performed. The specific number of animals used is not disclosed, but the breadth of studies suggests a volume within the 25,000–50,000 range annually.

Safe & Smart Tech

BridgeBio Pharma has implemented an information security program that incorporates elements of industry standards and frameworks such as NIST, ISO, and CIS.

The company engages third parties to conduct risk assessments, penetration testing, and vulnerability analyses. BridgeBio states it has measures to protect personal data from unauthorized access, use, and disclosure, and no specific incidents of unauthorized data use have been documented. The company reports experiencing general threats and security incidents, including phishing attacks and attacks on third-party vendor systems, but provides no quantitative data on specific data breaches, their frequency, or scale. BridgeBio processes personal data in accordance with applicable data protection regulations, including US and EU/UK laws, and uses EU-approved standard contractual clauses for international data transfers. They have appointed a Data Protection Officer for the EEA and UK. However, BridgeBio explicitly states it does not currently meet the threshold applicability requirements of U.S. state privacy laws, including the California Consumer Privacy Act (CCPA). The company attempts to limit and protect personal data processing, for example, by pseudonymizing information, and collects the minimum necessary information for regulatory obligations. Users are provided with rights to access, update, delete, object to, and transfer their personal data, and to withdraw consent for processing. BridgeBio states it does not engage in any automated decision-making.

Zero Waste & Sustainable Products

BridgeBio Pharma, Inc. ensures its waste handling and disposal practices comply with all relevant regulations.

Its facilities, which are LEED Platinum certified and CALGreen-compliant, promote recycling and composting and aim to reduce single-use plastics. However, the company's 2021 ESG report, from December 2021, lacks specific quantitative data on waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction percentages, take-back programs, circular design principles, waste reduction targets, supplier waste requirements, customer waste education, material efficiency, waste audit frequency, zero-waste certifications, or packaging-to-product ratios.